We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The FDA has awarded approval for what it says is its first drug for the treatment of multiple sclerosis (MS) in paediatric patients, giving the green light to Novartis’ Gilenya (fingolimod) specifically in relapsing forms of the disease following its desi